Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2525623 in Adults With Plaque Psoriasis
NCT01018810Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2009
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of LY2525623 in plaque psoriasis, sponsored by Eli Lilly and Company. Started Dec 2009; status: terminated.
02
Drugs
LY2525623
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01018810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018810.